Oragenics, Inc. — Q3 2011 Form 10-Q
Reporting period: Three and nine months ended September 30, 2011; filed November 14, 2011. Oragenics is a development-stage nutraceutical and biotechnology company, commercializing ProBiora3 oral probiotics while developing SMaRT Replacement Therapy, MU1140-S antibiotics and other technologies.
Financial performance and position
| Metric | Q3 2011 | Q3 2010 | Nine months 2011 | Nine months 2010 |
|---|---|---|---|---|
| Revenue | $350,351 | $364,574 | $1,047,857 | $1,010,753 |
| Gross profit (margin) | $215,940 (61.6%) | $217,317 (59.6%) | $489,652 (46.7%) | $537,175 (53.1%) |
| Operating expenses | $1,927,049 | $2,087,934 | $6,020,522 | $6,165,398 |
| Operating loss | $(1,711,109) | $(1,870,617) | $(5,530,870) | $(5,628,223) |
| Net loss | $(1,807,290) | $(1,875,228) | $(5,739,546) | $(5,632,650) |
| Basic and diluted loss per share | $(0.32) | $(0.34) | $(1.01) | $(1.03) |
- Nine-month operating cash use was $4,103,502, versus $4,676,576 in 2010. Financing provided $3,971,399; investing used no cash. Cash and cash equivalents were zero at September 30, while restricted cash was $382,923.
- At September 30, total assets were $1,229,049; current liabilities were $7,809,584, including $6 million due under the shareholder convertible revolving facility. Working capital deficit was $6,748,593; shareholders’ deficit was $6,580,535.
- After a further $1 million draw on October 5, the facility balance reached $7 million, its full amended commitment, leaving no further availability. The facility bears interest at LIBOR plus 6% and matures July 30, 2012; outstanding amounts may automatically convert in a future securities offering.
- Accumulated deficit was $39,056,594. Stock-based compensation was $1,058,327 for the first nine months, a noncash expense.
Changes versus comparable periods
- Q3 revenue declined 4% year over year, primarily from reduced mass-retail ProBiora3 sales, partly offset by grant revenue. Nine-month revenue increased about 4%, with ProBiora3 sales up $50,983 and grant revenue lower by $13,879.
- Nine-month gross profit fell $47,523 as cost of sales rose $84,627, including $127,144 in scrap expense related to product-transition costs. The company reported lower scrap expense in Q3 than in the prior-year quarter.
- Research and development expense rose 17% for the first nine months, reflecting SMaRT Phase 1 and LPT3-04 clinical-trial spending. SG&A fell 8%, mainly due to lower consulting, advertising and marketing, and professional-services costs, partly offset by higher stock-based compensation and board costs.
- Nine-month interest expense increased by $203,190, principally due to additional borrowing. The Q3 net loss improved year over year, but the nine-month net loss increased slightly.
- The company increased authorized common shares from 15 million to 50 million and expanded its stock-plan authorization from 625,000 to 1,125,000 shares. It was withdrawing from mass retail and shifting sales efforts toward direct-to-consumer, professional offices, private label, international distribution and licensing.
Outlook, risks and notable items
- Management said available resources were expected to fund the business as structured only through December 2011. It stated that additional capital was needed, with no committed funding source after the facility was fully drawn; financing may be unavailable or dilutive, and failure to raise funds could require cuts, delays or cessation of operations.
- The filing highlights substantial doubt about the company’s ability to continue as a going concern, consistent with the auditor’s 2010 report. The interim financial statements include no adjustments for the outcome of that uncertainty.
- Management expected SMaRT’s second Phase 1 trial to conclude in the first half of 2012, subject to enrollment. It expected to begin MU1140-S preclinical testing and file an IND in 2012 as capital permitted; results from the LPT3-04 weight-loss trial were expected in Q4 2011. These are forward-looking expectations, not assurances.
- Four retail and distributor accounts had guaranteed return rights; $28,623 of related revenue was deferred. Inventory included a $98,025 obsolescence reserve, and $21,157 of consigned inventory was fully reserved as the company planned to exit mass retail.
- Disclosure controls were deemed ineffective at September 30 because material weaknesses remained: limited control documentation, insufficient staff for segregation of duties, and inadequate formal accounting and reporting policies. Management reported remediation work was ongoing.
- Recent organizational changes included the marketing vice president’s departure and the chief scientific officer’s retirement from full-time service effective October 31, with consulting services expected thereafter.
- No material pending legal proceedings were reported. The filing identifies no material market-risk disclosures as applicable.
Important facts for investors to verify
- Whether the company obtained financing after the October 2011 draw and how long available cash actually supported operations.
- Whether product sales and any partnerships, licensing, grants or other funding met management’s expectations, and the effect of leaving mass retail.
- Enrollment and progress of the SMaRT Phase 1 trial, LPT3-04 trial results, and whether MU1140-S reached planned preclinical and IND milestones.
- Debt terms, interest burden, maturity and any conversion or dilution effects; also verify the fully diluted share count given outstanding options and warrants.
- Progress in remediating internal-control material weaknesses and any subsequent changes to the company’s going-concern assessment.